All Articles Tagged With: "MRI Contrast Agent"
Articles
Nephrogenic Systemic Fibrosis Settlements Reached by Bayer in 140 Cases
Bayer reports that it has reached settlement agreements with nearly half of the plaintiffs who have filed a Magnevist lawsuit, involving claims that the company’s gadolinium-based MRI contrasting agent caused users to develop a rare and potentially life-threatening condition, known as nephrogenic systemic fibrosis (NSF).
GE Healthcare Settles Libel Lawsuit Over Omniscan with Radiologist
GE Healthcare and a Danish scientist have reached a settlement in a libel lawsuit over statements made about the side effects of Omniscan, an MRI contrast agent that has been linked to nephrogenic systemic fibrosis (NSF), a severe and debilitating injury.
Radiologist Fights Back Against GE Healthcare Over Omniscan Side Effects
A Danish scientist is filing a counterclaim against GE Healthcare in response to libel charges originally brought by the company over critical statements the radiologist made about potential side effects of Omniscan, an MRI contrast agent that has been linked to a severe and debilitating injury among some patients, known as nephrogenic systemic fibrosis (NSF). [...]
Nephrogenic Systemic Fibrosis Lawsuit Scheduled For Trial in San Francisco
A date has been set for the start of what could be the first trial of a lawsuit involving nephrogenic systemic fibrosis (NSF), a severe and sometimes fatal condition caused by use of gadolinium based MRI contrast agents.
Nephrogenic Systemic Fibrosis Risk 77 Times Higher Among Dialysis Patients
The results of a new study into side effects of gadolinium MRI contrast agents indicates that patients undergoing dialysis are at 77 fold higher risk of contracting nephrogenic systemic fibrosis (NSF), and kidney transplant patients face a 69 fold higher risk of developing the rare and potentially life-threatening condition, which is associated with a hardening [...]
Optimark MRI Contrast Agent NSF Warning Updated
The makers of Optimark, a gadolinium-based MRI contrasting agent, are changing the warning label to indicate that Optimark should not be used by patients with severe kidney problems. The label change was made due to the increased risk a serious and potentially life threatening condition, known as nephrogenic systemic fibrosis (NSF), which can cause [...]
Nephrogenic Systemic Fibrosis Warnings to be Reviewed Again by FDA
An FDA advisory committee is planning to review a decision by the agency to place the same warning on all gadolinium-based MRI contrast agents about the risk of nephrogenic systemic fibrosis (NSF), as reports suggest that GE Healthcare’s Omniscan (gadodiamide) may be associated with a much greater risk for the debilitating and potentially life-threatening condition. [...]
Nephrogenic Systemic Fibrosis Settlements Being Negotiated on Bayer Magnevist Lawsuits
According to U.S. District Judge Dan Polster, Bayer Healthcare has initiated settlement negotiations with a number of plaintiffs who have filed Nephrogenic Systemic Fibrosis lawsuits after receiving the gadolinium-based Magnevist MRI contrast agent.
Gadolinium Litigation Judge May Not Preside Over First Trials
The federal judge overseeing the consolidated Gadolinium litigation involving cases filed on behalf of those who have developed Nephrogenic Systemic Fibrosis after receiving an MRI with contrast, has indicated that he will not preside over any of the first trials unless he is permitted to preside over an equal, or near equal, number of cases [...]
Gadolinium MRA Contrast Agent Approved by FDA with Warnings about Nephrogenic Systemic Fibrosis
The FDA has approved a new gadolinium-based contrast agent, Vasovist Injection, which is the first imaging agent approved for use during Magnetic Resonance Imaging (MRA) examinations.
